IP Library Granted Patent US 8,551,542
Granted Patent B1
US 8,551,542 · App. 13/623,110 · Granted Oct 8, 2013

Methods and compositions for increasing growth hormones

Inventors: Amy L. Heaton (Salt Lake City, UT); Mitchell K. Friedlander (Salt Lake City, UT); Dennis Gay (Salt Lake City, UT)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,551,542
App. No.
13/623,110
Granted
Oct 8, 2013
Kind
B1
Abstract

Embodiments of the invention generally relate to methods and supplements for improving the health of human beings.

Claims (35)

1. A nutritional supplement composition in unit dosage form, wherein the unit dosage consists of:

about 1 mmol L-arginine;

about 1 mmol Oxo-proline;

about 2 mmol L-lysine;

about 1.5 mmol N-acetyl L-cysteine;

about 2 μmol L-glutamine; and

about 125 μg Schizonepta (aerial parts) powder.

2. The nutritional supplement composition of claim 1 , wherein the unit dosage form consists of:

0.86 mmol L-arginine;

1.32 mmol Oxo-proline;

2.05 mmol L-lysine;

1.53 μmol N-acetyl L-cysteine;

1.71 μmol L-glutamine; and

125 μg Schizonepta (aerial parts) powder.

3. The nutritional supplement composition of claim 2 , wherein the unit dosage form consists of 181.38 mg L-arginine HCl; 170.93 mg L-pyroglutamic acid; 374.83 mg L-lysine HCl; 0.25 mg N-acetyl L-cysteine USP; 0.25 mg L-glutamine; and 0.125 mg Schizonepta (aerial parts) powder.

4. The nutritional supplement composition of claim 1 , wherein the nutritional supplement unit dosage form is in capsule form.

5. A nutritional supplement composition in unit dosage form, wherein the unit dosage form consists of:

3.44 mmol L-arginine;

5.30 mmol Oxo-proline;

8.21 mmol L-lysine;

6.13 μmol N-acetyl L-cysteine;

6.84 μmol L-glutamine; and

0.50 mg Schizonepta (aerial parts) powder.

6. The nutritional supplement composition of claim 5 , wherein the unit dosage form consists of 725.50 mg L-arginine HCl; 683.70 mg L-pyroglutamic acid; 1499.30 mg L-lysine HCl; 1.00 mg N-acetyl L-cysteine USP; 1.00 mg L-glutamine; and 0.50 mg Schizonepta (aerial parts) powder.

7. A method for improving health in a human being, the method comprising orally administering an effective amount of the nutritional supplement unit composition of claim 2 to a subject in need thereof.

8. The method according to claim 7 , wherein the nutritional supplement unit dosage form is administered to the human being, so as to increase lean body mass; reduce obesity, adipose tissue mass, or anxiety; support weight loss; decrease appetite and atrophic processes in skeletal muscle, liver, kidney, spleen, skin, or bone; and/or improve energy, endurance, sleep, metabolism, heart rate, blood pressure, cardiovascular health, sympathetic nervous activity, thyroid response, fat metabolism, glucose utilization, mental/cognitive function, reaction time, bone density, hair health and appearance, nail health and appearance, skin health and appearance, and/or libido.

9. The method according to claim 7 , wherein the nutritional supplement unit dosage form is orally administered in a total amount of 2.9 grams.

10. The method according to claim 7 , wherein the nutritional supplement is administered from one to three times daily.

11. The method according to claim 7 , wherein the nutritional supplement is administered once a week.

12. The method according to claim 7 , wherein the nutritional supplement is administered on an empty stomach.

13. The method according to claim 7 , wherein the human being is at least 30 years old.

14. The method according to claim 7 , wherein the human being exhibits one or more symptoms of post-traumatic stress disorder selected from the group consisting of re-experiencing the original trauma(s) through flashbacks or nightmares, avoidance of stimuli associated with the trauma, increased arousal, difficulty falling or staying asleep, anger, and hypervigilance.

15. A method for improving health in a human being by increasing levels of human growth hormone in the human being, the method comprising:

orally administering to a subject in need thereof a nutritional supplement to the human being, wherein the nutritional supplement consists of 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 μmol N-acetyl L-cysteine; 6.84 μmol L-glutamine; and 0.50 mg Schizonepta (aerial parts) powder.

16. The method according to claim 15 , wherein the nutritional supplement consists of 725.50 mg L-arginine HCl; 683.70 mg L-pyroglutamic acid; 1499.30 mg L-lysine HCl; 1.00 mg N-acetyl L-cysteine USP; 1.00 mg L-glutamine; and 0.50 mg Schizonepta (aerial parts) powder.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 5, 2023
From: CASPAR CAPITAL LP
To: QUALITY IP HOLDINGS LLC
Reel/Frame 062283/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2022
From: CERBERUS BUSINESS FINANCE, LLC
To: CASPAR CAPITAL LP
Reel/Frame 061636/0625 →
ASSIGNMENT OF SECURITY INTEREST Recorded Dec 30, 2019
From: LS2, LLC
To: CERBERUS BUSINESS FINANCE, LLC
Reel/Frame 051447/0114 →
SECURITY INTEREST Recorded Aug 21, 2015
From: QUALITY IP HOLDINGS, LLC
To: LS2, LLC
Reel/Frame 036392/0053 →
ASSIGNMENT FOR SECURITY - PATENTS Recorded Dec 4, 2014
From: QUALITY IP HOLDINGS, LLC
To: CERBERUS BUSINESS FINANCE, LLC, AS COLLATERAL AGENT
Reel/Frame 034535/0294 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 032089 FRAME 0963. ASSIGNOR(S) HEREBY CONFIRMS THE NAME OF THE ASSIGNEE IS QUALITY IP HOLDINGS, LLC. Recorded Jul 14, 2014
From: HEATON, AMY L.; FRIEDLANDER, MITCHELL K.; GAY, DENNIS
To: QUALITY IP HOLDINGS, LLC
Reel/Frame 033312/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2014
From: HEATON, AMY L.; FRIEDLANDER, MITCHELL K.; GAY, DENNIS
To: QUALITY IP HOLDINGS, INC.
Reel/Frame 032089/0963 →